Dr Karen O’Hanlon

Dr O’Hanlon is Chief Development Officer at Stablepharma, previously holding the position of VP of Clinical Operations at Boyds Consulting. She is leading the clinical development of SPVX02 in collaboration with the University Hospital Southampton NHS Foundation Trust.

Karen has a PhD in Biochemistry and Molecular Biology from Manchester University and has worked in clinical drug development for over 20 years. Along with many other skills, Karen is an expert in the translation design, strategic planning and conduct of early phase clinical trials and she has worked on studies across the EU, with a focus on Vaccines and advanced therapies.